Compare · INDV vs NVS
INDV vs NVS
Side-by-side comparison of Indivior Pharmaceuticals Inc. (INDV) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INDV and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $284.62B, about 60.6x INDV ($4.69B).
- Over the past year, INDV is up 180.0% and NVS is up 26.3% - INDV leads by 153.7 points.
- INDV has hit the wire 1 time in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 6 for INDV).
- Company
- Indivior Pharmaceuticals Inc.
- Novartis AG
- Price
- $37.60+0.43%
- $149.07+0.43%
- Market cap
- $4.69B
- $284.62B
- 1M return
- -7.42%
- +0.52%
- 1Y return
- +179.97%
- +26.30%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 0
- Recent ratings
- 6
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest INDV
- New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
- Indivior Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
- Director Thompson Juliet covered exercise/tax liability with 1,117 shares and was granted 6,518 shares, increasing direct ownership by 71% to 12,973 units (SEC Form 4) (withholding tax)
- Director Humphreys Keith was granted 6,518 shares, increasing direct ownership by 68% to 16,042 units (SEC Form 4)
- Director Kingsley Stuart A was granted 6,518 shares, increasing direct ownership by 117% to 12,100 units (SEC Form 4)
- Director Ninivaggi Daniel A was granted 6,518 shares, increasing direct ownership by 32% to 27,163 units (SEC Form 4)
- Director Ryan Barbara was granted 6,518 shares, increasing direct ownership by 114% to 12,242 units (SEC Form 4)
- Director Stejbach Mark was granted 6,518 shares, increasing direct ownership by 32% to 27,087 units (SEC Form 4)
- Director Wheadon David E. was granted 10,430 shares, increasing direct ownership by 51% to 30,780 units (SEC Form 4)
- Indivior to Participate in Upcoming Investor Conferences
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG